Name | Title | Contact Details |
---|
MicroOptx is an early stage medical device company that is building a platform technology to shunt aqueous humor from the anterior chamber to the surface of the eye. Our mission is to change the way the World treats glaucoma – halting the devastating effects of this progressive disease. MicroOptx is led by recognized medical, industry and financial veterans who are dedicated towards preventing blindness.
Allied Healthcare Systems is a Jamestown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hospira is the world`s leading provider of injectable drugs and infusion technologies. Through our broad, integrated portfolio, we are uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Through our offering of high-quality, lower-cost generic medications, we continue to help reduce the overall costs of healthcare — to improve both the affordability of care for patients and the financial strength of the global healthcare system. By working with our device customers to integrate technologies at the point of care, we are the partner of choice for improving patient and caregiver safety, clinical outcomes, cost management, as well as caregiver efficiency and effectiveness. Additionally, our One2One™ business is a leading provider of contract manufacturing services to proprietary pharmaceutical and biotechnology companies for formulation development, filling and finishing of injectable pharmaceuticals. At Hospira, we have the opportunity to Make a Difference every day by positively impacting the lives of our customers and patients and delivering value to all of our stakeholders.
AEIOMED is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel`s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.